Skip to content

Demonstrate the Effectiveness to Hemopatch in Controlling Postoperative Bleeding After Laparoscopic Cholecistectomy and in Reducing of Morbidity and Postoperative Hospital Stay

Efficacy of Hemopatch in Reducing of Postoperative Bleeding After Laparoscopic Cholecystectomy: Prosective and Multicenter Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02777307
Enrollment
150
Registered
2016-05-19
Start date
2016-06-30
Completion date
2017-05-31
Last updated
2016-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy of Hemopatch in Controlling of Postoperative Bleeding or Reducing of Postperative Morbidity After Laparoscopic Cholecistectomy

Keywords

Laparoscopic, Cholecistectomy, Collection, Bleeding, reoperation

Brief summary

Demonstrate the effectiveness to Hemopatch in controlling postoperative bleeding or reducing of postperative fluid collection after laparoscopic cholecistectomy, morbidity and postoperative hospital stay.

Detailed description

Prospective Multicenter Longitudinal and cohort. The sample size of 150 patients was calculated in order to obtain a statistical power adequacy or higher (Type I error - Alpha = 0.05, Type II Error - Beta = 0:20), assuming the 1-day to reduce the postoperative stay with use Hemopatch compared to the control (average stay little 3 +/- 2 days). Primary endpoint: \- significant reduction in postoperative hospital stay Secondary endpoints: * reduction of subhepatic blood liquid volume * reduction of liver hematoma * reduction of postooperative complications as deep surgical site * reduction rates of reoperation * reduction in readmission rates * postoperative pain on the VAS scale 1-10. The results obtained in relation to primary and secondary objectives will be compared with a control group of case-matched. Inclusion Criteria: \- Between the ages of 18-75 years, calculus of gallbladder (micro- and macro-lithiasis), polyp/neoplasm of gallbladder Exclusion Criteria: \- Coagulopathies, medication with antiplatelet drugs, ASA \> 3, acute cholecystitis, simultaneous calculus of main biliary duct, acute pancreatitis. The patient will enroll if cholecystectomy is performed laparoscopically, if it is not a complication occurred intraoperative type: iatrogenic enterotomy suture intestinal, iatrogenic lesion of liver parenchyma, bile duct injury. The patient will exclude from the study if one of these intraoperative complication will occur. The patient leaves the protocol if the dissection is done through energy-devices (ultrasound or radiofrequency). At the end of the laparoscopic cholecstectomy, Hemopatch will be inserted into the peritoneal cavity through the port of 10-12 mm and laid on the cavity of the gallbladder and a drainage will be systematically placed. It will be given a first-generation cephalosporin antibiotic (one shot). At 24 hours of VLC a liver ultrasound will be performed and recorded: evaluation of presence of perihepatic fluid, collection or haematoma. It will be noted the volume of drainage which will be removed in first postoperative day. In case of delay removal of drainage, it will be recorded. It will be assessed postoperative pain by VAS scales to 6-12-24 h after surgery. Re-operations and re-hospitalizations will be recorded in prospective data. Statistical analyzes were performed using the software SPSS for Mac, 22nd edition (SPSS Software, Inc., IL, Chicago). The differences in the distributions will be calculated using the chi-square test or Fisher exact test, depending on the number of cases in the various subgroups and by comparing means (Student t-test, one-way ANOVA test). The p \< 0.1 will be used as the cut-off for statistical significance in the selection of variables of multivariate analysis in order not to drop important potential predictors. The statistical significance is conventionally defined with p \<0.05 in all cases considered. All eligible patients will be adequately informed and informed consent will be signed. The Study will be conducted according to ethical requirements, following the Declaration of Helsinki, and good clinical practice.

Interventions

Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy

Sponsors

Azienda Ospedaliera San Gerardo di Monza
CollaboratorOTHER
San Giuseppe Moscati Hospital
CollaboratorOTHER
Ospedali Riuniti di Foggia
CollaboratorOTHER
Ospedale Regina Apostolorum
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Gallbladder stone * Polyp/neoplasm of gallbladder

Exclusion criteria

* Coagulopathies, * Medication with antiplatelet agents * ASA \> 3 * Acute cholecystitis * Main biliaru duct stone * Acute pancreatitis

Design outcomes

Primary

MeasureTime frame
significant reduction in postoperative hospital stay1 year

Secondary

MeasureTime frame
reducing of liver hematoma1 year
reducing of postoperative complications1 year
reducing of subhepatic volume drainage1 year
reducing of re-hospitalization1 year
To assess postoperative pain by the VAS scale 1-10.1 year
reducing of rates of reoperation1 year

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026